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Introduction
Wolfram syndrome (WFS), also known as DIDMOAD, 
is a rare inherited disease first described in 1938 by 
Wolfram and Wagener [1, 2]. It is characterized by 
diabetes insipidus (DI), diabetes mellitus (DM), optic 
atrophy (OA), and deafness. Urological, psychological, 
and neurological comorbidities may also be present. 
Wolfram syndrome is very rare. Its prevalence has 
been estimated at 1 in 770,000 individuals in the UK, 1 in 
500,000 in Germany, 1 in 710,000 in the Japanese popula-
tion, and 1 in 68,000 in the Lebanese population. The 
highest prevalence, of 1 in 54,478, is in a small district in 
a Sicilian population [2–6]. The high prevalence of WFS 
in Lebanese and Sicilian populations could be due to the 
high rates of consanguinity in these populations [7, 8]. 
Because WFS is a progressive disorder, and affected 
individuals experience a wide spectrum of symptoms 
during their lifetimes. The lifespans of affected indi-
viduals are generally shortened as a consequence of 
neurological and psychiatric problems, such as central 
respiratory failure, food aspiration, and suicide. Cur-
rently, no therapeutic intervention is known to alter 
the progression or the life expectancy of the affected 
individuals [9].
Several loss-of-function mutations of the Wolfram 
syndrome 1 gene (WFS1) have been described in pa-
tients with WFS [4]. WFS1-deficient mice have glucose 
intolerance associated with loss of pancreatic beta 
cells. The gene product of WFS1 is an endoplasmic re-
ticulum embedded protein, which has been implicated 
in various cellular functions such as insulin secretion 
and processing, cell cycle regulation, unfolded protein 
response, and cAMP production [10–15]. On the other 
hand, WFS1 mutation was not identified in some pa-
tients, providing evidence of genetic heterogeneity 
for this disease. A specific mutation in a second gene 
(WFS2), also known as CISD2, has been described in 
affected Jordanian families [16].
The natural history of WFS has been characterized 
in different populations, mainly Asian populations, and 
there are few singles in occidental European populations. 
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all of them in paediatric age, and consisted of diabetes 
mellitus in 9 patients (81%), OA in another patient, and 
DI in another one. The median age of DM, OA, DI, and 
urological disorders at onset was 6 (range 2–11 years), 14 
(range 5–30 years), 13 (range 10–16 years), and 10 (range 
8–10 years), respectively. Hearing loss (HL) developed 
at the median age of 8 years (range 6–15 years).
Nine patients have diabetes and are currently treat-
ed with insulin, in a median dose of 0.7 units/kg/day. 
The current median HbA1c is 7.5% (range 7–9.5%). 
Mild hypoglycaemia was found in all patients, and 
non-proliferative retinopathy was found in 1 patient 
who had had diabetes for 20 years.
Optic atrophy was bilateral and progressive in all 
patients, and presented as hypoplasia, visual field de-
fect, and colour blindness — all of them diagnosed in 
paediatric age.
Three patients presented DI, all of them diagnosed 
in adolescence. Urological abnormalities including 
residual urine in the bladder and urinary incontinence 
were established by imaging examinations in 5 (45.4%) 
of the 11 patients. 
All patients had mutations in WFS1. Eight patients 
(72.7%) had a broad spectrum of recessive mutations 
in WFS1. Three patients (27.2%) had mutations in only 
1 allele. Ages at onset of DM in patients with recessive 
WFS1 mutations were lower than those in patients with 
1 mutation in only 1 allele. 
Two patients had changes in brain MRI at this time, 
which showed atrophy of the cerebellum and brain 
stem, 1 of them with recent hospitalization in intensive 
care for acute respiratory failure. The overall survival 
rate was 100% at the time of follow-up, and the age of 
patients ranged from 12 to 34 years.
Material and methods
We retrospectively analysed all WFS patients diagnosed between 
1990 and 2020 in the Centro Hospitalar São João, a tertiary hospital 
in Northern Portugal. 
We screened a total of 14 patients who were eligible for our study 
due to the fact that they had diagnostic clinical criteria and iden-
tification of WFS1 mutations. One patient clinically suspected of 
WFS was excluded because he had no genetic confirmation, and 
2 patients with clinical and genetic confirmation were excluded 
because they had no follow-up in our hospital in adult life. 
Demographic data, clinical presentation, including signs and symp-
toms, and their onset age, family history, and genetic analysis were 
retrospectively abstracted from clinical records. 
Descriptive statistics were expressed for quantitative data by the 
median. They were presented for categorical data as the number 
and percentage.
Results
Our population comprised 11 WFS patients, with 7 
females (63%) and a median current age of 23 years 
(range 12–34 years). Two patients were siblings. The 
patients’ clinical features are summarized in Table 1. 
Four patients (36.3%) had all 4 components of DID-
MOAD. OA was present in all patients. Diabetes 
mellitus was present in 9 (81.8%) patients, and the 
other 2 patients had impaired glucose tolerance (IGT) 
rather than DM. Eight patients (72.7%) presented with 
psychiatric disorders. Urological abnormalities were 
present in 5 of the 11 patients (45.4%). Five patients 
also had neurological disorders. Four patients (36.4%) 
had insipidus diabetes, and 4 patients (36.4%) also had 
hearing impairment. One patient presented a rheuma-
tological disorder: undifferentiated arthritis in need of 
biological treatment. 
The first clinical manifestation of the disease oc-
curred at a median age of 7 years (range 2–15 years), 
Table 1. Demographic features of the patients and detailed clinical presentations
Case nº Onset age [yrs] Sex DM/IGT OA DI HL UD ND PD
1 8 M Yes Yes Yes Yes Yes Yes Yes
2 3 F Yes Yes Yes Yes Yes Yes Yes
3 3 F Yes Yes No No Yes No Yes
4 6 M Yes Yes No No No No Yes
5 7 M Yes Yes No No No No Yes
6 7 F Yes Yes No No No Yes Yes
7 6 M Yes Yes No No No No No
8 14 F Yes Yes Yes Yes Yes No Yes
9 15 F Yes Yes No No No No No
10 11 F Yes Yes Yes Yes No Yes Yes
11 6 F Yes Yes No No Yes Yes No
M — male; F — female; DM — diabetes mellitus; IGT — impaired glucose tolerance; OA — optic atrophy; DI — diabetes insipidus; HL — hearing loss;  
UD — urological disorder; ND — neurological disorder; PD — psychological disorder
355











In this study, we retrospectively described the clinical 
features of 11 WFS patients from a single centre in the 
last 30 years.
Diabetes mellitus was the most common clinical 
feature in our cohort, in accordance with previous 
studies. Non-auto-immune insulin-dependent DM is 
the first manifestation of WFS, but there is a great diag-
nostic delay from the onset of diabetes to the diagnosis 
of the syndrome. Zmyslowska et al. found that WFS1 
was diagnosed with a delay of at least 7 years, and 
that all WFS1 patients were primarily misdiagnosed as 
having insulin-dependent type 1 DM [17]. This could 
be a limitation of our study.
Microvascular complications are rare, and they 
do not progress as quickly as in the type 1 DM. WFS1 
non-autoimmune insulin-dependent DM is charac-
terized by a daily insulin requirement and a mean 
HbA1c lower than in type 1 DM, because in WFS1 the 
residual insulin secretion lasts longer than in type 1 
DM. In our sample, we verified the same tendency. 
Non-autoimmune insulin-dependent DM of WFS 
begins in preschool-age without ketoacidosis, it is 
antibody-negative, and has surprisingly long periods of 
remission. Therefore, WFS must be suspected in these 
cases [18–20].
Optic atrophy is usually present in the diagnosis of 
WFS.  In these patients, OA occurs in the first decade; 
it is progressive and often leads to blindness. It begins 
at an average age of 11 years (6 weeks to 19 years) with 
reduced visual acuity and loss of colour vision [2, 18]. 
The median age of diagnosis of OA in our patients was 
14 years. Hence, in WFS patients, an annual eye exami-
nation is essential, including visual acuity, colour vision 
testing, fundoscopy, visual field, and optical coherence 
tomography scan. The monitoring of the efficacy of 
potential therapy can be performed by visual evoked 
potentials [6].
In WFS patients, diabetes mellitus usually occurs in 
the first decade of life, OA is diagnosed during the early 
second decade, DI and HL during the second decade, 
and urological and neurological abnormalities during 
10–30 years [21–23], as in our study. 
Generally sensorineural deafness presents at an av-
erage age of 12–16 years (range 5–39 years) and is a fea-
ture seen in 62% of WFS patients [2, 9]. This disorder 
affects high frequencies first and progresses relatively 
slowly [2]. Pennings et al. found that in WFS females, 
hearing loss was more prevalent than in WFSF1 males 
[24]. However, in other studies, no gender differences 
in the degree of deafness were found [2, 25]. In our 
study, we found that 2 females and 1 male presented 
this disorder. The follow-up of this disorder in WFS 
patients includes an audiometry test every year or 
every 2 years [6].
Neurological complications and psychiatric disorders 
are frequent in WFS patients. In our study, the incidence 
of neurological complications was 45%. The most com-
mon symptom is cerebellar ataxia, as in our study. Head-
ache has also been reported in WFS [4] — 5 patients in 
our study presented headache. These patients should 
be evaluated yearly or twice a year by a neurologist.
Urinary tract problems are another major clinical 
challenge for Wolfram syndrome patients, affecting 
60–90% of this population [26]. Hydroureteronephrosis, 
urinary incontinence, and recurrent infections are com-
mon signs of neurogenic bladder. The median age of 
onset of urological manifestations is 20 years, although 
numerous patients develop the symptoms at 10–20 
years of age [6, 28]. We reported urological abnormali-
ties in 45.4% of patients.
Frequently (up to 20–30%) WFSF patients are affect-
ed by episodes of severe depression, psychosis, smell 
and sleep abnormalities, or organic brain symptoms, as 
well as impulsive verbal and physical aggression, while 
WFS1 heterozygotes may be predisposed to psychiatric 
illness. Usually, cognitive and psychiatric symptoms 
begin in the later stages of the disease [4, 26–28]. In 
our case, we found a high number of patients with this 
pathology, given that up 72% of our patients presented 
psychiatric disorders from adolescence onwards.
Genetic analysis should be considered as an effective 
method to assist diagnosis and genetic consultation [6]
Wolfram syndrome has high morbidity and mortal-
ity, without effective treatment, and the median age 
of death is around 30 years (range 25–49). Respiratory 
failure or dysphagia due to brainstem involvement are 
common causes of mortality [6, 29]. In our case, thus 
far the survival rate is 100%, with the age of patients 
ranging from 12 to 34 years.
More studies are necessary to better manage this 
devastating disease and to guarantee the patients a bet-
ter quality of life and longer life expectancy [30].
Conclusions
The information obtained in this study can facilitate 
further research in an attempt to improve prevention 
strategies, as well as treatments for this devastating 
disease.
In the author ’s opinion, Wolfram syndrome, as 
a multisystemic progressive disease requiring rapid 
diagnosis, should be followed up in tertiary hospital 
centres, by a multidisciplinary team. Special care should 
be taken in the transition into adulthood follow-up, 
taking into account that the greatest worsening of the 
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